Historical Background and the Safety Tragedy
In 1956, thalidomide was introduced to the global market as an innovative, 'miracle' safe sleeping aid that was not a barbiturate derivative. The drug was actively prescribed to pregnant women to relieve morning sickness.
However, in 1961, it was discovered that the drug causes severe embryonic developmental disorders. Due to its catastrophic teratogenic effect, thalidomide was urgently recalled from all markets. This historical precedent forced the pharmaceutical industry to completely revise standards for preclinical testing and drug safety control.
Modern Pharmacodynamics and Mechanism of Action
Decades later, scientists returned to studying the drug, re-evaluating its properties. Today, thalidomide and its analogs (such as lenalidomide) are regarded as potent anti-inflammatory and immunomodulatory agents.
Key pharmacological effects include:
- Primary pathway: inhibition of tumor necrosis factor-alpha (TNF-α) activity.
- Reduction of neutrophil phagocytic activity.
- Upregulation of interleukin-10 (IL-10) expression.
Clinical Application
Due to its immunomodulatory profile, thalidomide has found a narrow but important niche in modern medical practice.
Approved indications:
- Multiple myeloma.
- Leprosy.
In addition, the drug is undergoing active clinical trials as a promising treatment for autoimmune pathologies (rheumatoid arthritis, Crohn's disease), certain infections (AIDS), and solid tumors (colorectal cancer, melanoma, renal cell carcinoma, and prostate cancer).
Safety Profile and Adverse Reactions
The use of the drug requires the strictest control due to a substantial list of side effects. Pregnancy remains the main contraindication due to the high risk of birth defects.
Other dangerous and frequent adverse reactions include:
- Peripheral neuropathy.
- Significantly increased risk of deep vein thrombosis.
- Hypothyroidism.
- General symptoms: constipation, skin rash, and fatigue.